NCT00646035已完成3 期
A Phase III, Prospective, Placebo-Controlled, Double-Blind, Randomized, Multi-Center Study to Evaluate the Safety and Efficacy of Paricalcitol Capsules in Reducing Serum Intact Parathyroid Hormone Levels in End Stage Renal Disease Subjects on Peritoneal Dialysis
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Abbott
- 入组人数
- 75
- 主要终点
- The achievement of two consecutive greater than or equal to 30% decreases from baseline iPTH levels.
研究概览
简要总结
To determine the safety and efficacy of paricalcitol capsules as compared to placebo for treatment of secondary hyperparathyroidism by decreasing serum intact parathyroid hormone levels in end stage renal disease subjects on peritoneal dialysis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject is greater than or equal to 18 years.
- •Subject is diagnosed with ESRD and must be on continuous PD 7 days per week for at least 2 months prior to Screening Phase.
- •If female, subject is either not of childbearing potential or is of childbearing potential and practicing one of the recommended methods of birth control.
- •If female, subject must have a negative serum pregnancy test prior to treatment.
- •If female, subject is not breastfeeding.
- •Subject is undergoing full PD regimen and is expected to remain on this PD regimen for the duration of the study.
- •For those subjects who have been taking a phosphate binder prior to therapy, the subject has been on a stable type of phosphate binder at least 4 weeks prior to the Pre-Treatment Phase.
- •For entry into the Pretreatment Phase the subject must have: Calcium level less than or equal to 10.5 mg/dL and Ca x P level less than or equal to
- •For entry into the Treatment Phase the subject must have: iPTH greater than or equal to 300 pg/mL, calcium level of 8.0 to 10.5 mg/dL, inclusive, and Ca x P less than or equal to
- •Subject has voluntarily signed and dated an IRB approved informed consent.
排除标准
- •Subject has history of an allergic reaction or significant sensitivity to drugs similar to the study drug
- •Subject has had active peritonitis within 1 month prior to screening phase.
- •Subject has had more than one episode of peritonitis within 4 months prior to screening phase.
- •Subject has received a partial parathyroidectomy within 1 year prior to screening phase.
- •Subject has had acute renal failure within 3 months of screening phase.
- •Subject has chronic gastrointestinal disease.
- •Subject has taken aluminum-containing phosphate binders for greater than 3 weeks in the last 3 months prior to the screening phase or will require these medications greater than 3 weeks in the study.
- •Subject has a current malignancy or clinically significant liver disease.
- •Subject has a history of drug or alcohol abuse within 6 months prior to screening phase.
- •Subject has evidence of poor compliance with diet, medication, or PD.
- •Subject has participated in any investigational drug or device study within 4 weeks prior to the treatment phase.
- •Subject is taking maintenance calcitonin, glucocorticoids, or other drugs that may affect calcium or bone metabolism, other than females on stable estrogen and/or progestin therapy.
- •For any reason, subject is considered by the investigator to be an unsuitable candidate to receive paricalcitol capsules.
- •Subject is known to be HIV positive.
研究组 & 干预措施
A
Placebo Comparator
干预措施: paricalcitol capsules (Drug)
B
Placebo Comparator
干预措施: paricalcitol capsules (Drug)
结局指标
主要结局
The achievement of two consecutive greater than or equal to 30% decreases from baseline iPTH levels.
时间窗: 12 weeks
The incidence of clinically meaningful hypercalcemia and elevated Ca x P.
时间窗: 12 weeks
次要结局
未报告次要终点
研究者
相似试验
终止
4 期
Efficacy and Safety of Paricalcitol on the Treatment of Secondary Hyperparathyroidism in Calcitriol Resistant Dialysis SubjectsSecondary HyperparathyroidismDialysisNCT00664430Abbott13
招募中
不适用
A Observational Study to Evaluate the Efficacy and Safety of Pacitol Inj.Chronic Kidney Disease 5DSecondary HyperparathyroidismNCT06126016Boryung Pharmaceutical Co., Ltd1,000
已完成
不适用
Safety and Efficacy Study of Paricalcitol Versus Calcitriol in the Treatment of Secondary HyperparathyroidismKidney DiseaseHyperparathyroidismNCT00800358Penang Hospital, Malaysia69
已完成
2 期
Paricalcitol Compared to Maxacalcitol in Chronic Kidney Disease Patients With Secondary HyperparathyroidismSecondary HyperparathyroidismHemodialysisNCT00990704Abbott47
已完成
3 期
A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or HemodialysisEnd-Stage Renal DiseaseSecondary HyperparathyroidismNCT01382212AbbVie (prior sponsor, Abbott)13